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Abstract 
Introduction: There have been concerns in Korea that the availability of cheaper generics can appreciably increase 
prescribed volumes thereby negating their beneficial effects on overall pharmaceutical expenditure.  Objectives: 
Explore market changes after newly entered generics including market expansion and substitution effects, and to 
examine factors contributing to the prescribing of newly entered generics using atorvastatin as an exemplar. This is 
because previous studies have shown market expansion had occurred following generic atorvastatin. Methods: 
Explore market expansion effects by extracting all statins users from July 2008 to June 2010 from the nationally 
representative dataset of 2008, combined with the National Health Insurance Claims data, with atorvastatin¶VSDWHQW
expiring in July 2008. The data consisted of medical visit episodes of patients who had been prescribed statins at least 
once during the observational period. Patients who had been prescribed any statin before the observation period were 
classified as the previously treated group and those who had not as the newly treated group. Descriptive time series 
analysis was conducted and the mixed logit model applied to understand factors contributing to generic atorvastatin 
prescriptions. Results: Market expansion was observed after generic atorvastatin availability with an appreciable 
increase in number of newly treated patients, whereas substitution effect was found among previously treated patients. 
Newly treated patients tended to get significantly lower daily doses (p<0.0001). According to the mixed logistic 
analysis, newly treated patients were more likely to be prescribed generic atorvastatin (OR=2.58; 95% CI, 2.05-3.26) 
than their counterparts. Clinicians and secondary hospitals were also key drivers of generic atorvastatin (ORs were 
10.41 and 9.81, respectively). Conclusions: Newly marketed generic statins in Korea resulted in an expanding 
market by substantially increasing the number of new patients with clinics and hospitals appreciably using newly 
marketed generics. However lower doses of statins were prescribed. Policy makers do recognize that generic 
availability can save costs so should be encouraged. However, this is a concern when generic availability appreciably 
expands the market, potentially increasing the financial burden. This needs to be addressed. Additionally in Korea, the 
quality of prescribing should be monitored, especially focusing on clinics and secondary hospitals.  
Key words: generics, market expansion, Korea, statins, health policy 
Introduction 
Many countries are pursuing policies of encouraging the utilization of less costly generic medicines to cut spending 
and ensure efficient resource distribution. It is generally believed that generic medicines are less expensive copies of 
originators with the same therapeutic effects and the potential for appreciable savings [1-11]. Considerable resources 
can also be saved without compromising patient care by encouraging the prescribing of low costs generics versus 
more expensive patented products in classes where all products are seen as essentially similar at therapeutic doses. 
These include the proton pump inhibitors (PPIs), renin-angiotensin inhibitors and statins [6, 12-16]. However, the 
actual cost-savings arising from increased utilization of generics versus originators vary from country to country 
depending on the pricing policies for generics in that country as well as the extent of demand-side measures 
encouraging their prescribing [3-8]. The prerequisite for yielding appreciable cost-savings is that originators are 
2 
 
substituted by less costly generics and the overall volume of consumption does not undergo significant changes.  
However, according to the report of an analysis conducted by Kanovas et al (2008), no such savings were realized in 
the seven key OECD countries despite low prices and higher generic penetration [9]. This may be due to different 
policies across countries enhancing the prescribing of generics versus patented products in a class, with 
pharmaceutical companies continuing to promote their patented medicines, which can be up to 20 to 30 times more 
expensive than low cost generics. As a result, reducing potential savings [6, 13, 17]. In addition, the rise in elderly 
populations across countries with greater prevalence of chronic diseases is leading to increased polypharmacy [18-19], 
which coupled with improved management of chronic diseases such as increased use of statins at higher doses in 
patients at high risk of cardiovascular disease and greater control of blood pressure in patients with diabetes [12, 20], 
is increasing medicine consumption affecting potential savings.  
Kwon and Yang (2011) identified that no substitution effects were found after the entry of generics in Korea. with the 
utilization of both generics and originators rising substantially after generic entry. , For example, the utilisation of 
glimepiride increased 22-fold after the introduction of generics [21]. Consequently, the off-patent market in South 
Korea tends to expand upon the introduction of generic drugs without any apparent substitution effect [21].  
Particularly in Korea, pricing policies have traditionally focused on price cuts, under the assumption that lowering 
prices would directly curtail drug expenditures. However, the launch of an appreciable number of cheaper generics 
resulted in an increase, rather than a decrease, in drug expenditures by expanding the market along with an 
appreciable increase in their utilization. Kwon et al [22] identified that the market expansion of antihyperlipidemic 
medicines in recent years was mainly attributed to the increase in the number of patients prescribed atorvastatin 
following patent expiration. Other studies also demonstrated that the quantity of statins prescribed significantly 
increased in Korea following patent expiration, especially atorvastatin [23-24]. When faced with such findings 
indicating that the introduction of less costly generics contributes to increasing drug spending in Korea, and potentially 
other countries, by inducing market expansion instead of bringing about expected cost savings, further studies are 
needed to identify which factors contribute to market expansion to guide future policies in these countries. 
Consequently, this study aims to explore patterns of generic prescriptions among the statins (antihyperlipidemic 
agents) and subsequently examine factors contributing to the market expansion after atorvastatin patent expiration 
using the national health insurance (NHI) claims data in Korean context. The findings will be used to provide future 
guidance to the NIH and other key stakeholder groups. This builds on our previous findings with the statins [21-22].  
 
Methods  
Data source and study population 
This study is based on two merged datasets. One is the nationally representative dataset of 2008, which was a 
nationwide stratified, multistage probability sampling design used in consideration of the location and residence-type 
in order to establish full representativeness for the whole nation [25]. We merged this dataset with the Korean national 
health insurance (NHI) claims data from 2007 to 2010 using a de-identified code of each individual provided by the 
Health Insurance Review and Assessment Agency.  
As a result, the analysis of the dataset used in this study was based on the medical service utilization records of a 
nationwide representative sample population. The merged Korean NHI claims data comprises the medical service 
utilization data of the sample population classified into treatment data, prescription data, and illness data. The 
prescription data carries information on the date of the prescription, the name of the prescribed medicine, its dose and 
duration of medication, its purchase price, disease code, and type of medical institution. Details of the disease for 
which medication is prescribed are described in the 10th revision of the International Statistical Classification (ICD-10). 
However, since NHI claims data does not provide laboratory data for diagnosis, diagnostic accuracy cannot be verified. 
This limitation often results in inaccuracies in estimations of the prevalence and incidence of diseases. Despite this 
disadvantage, NHI claims data have a great advantage of being a complete dataset, allowing the tracking of medical 
service utilization patterns of the entire Korean population. 
Our study population was extracted from the dataset that covers the observation period of two years between July 
2008 (patent expiration of atorvastatin) and June 2010. Included in the analysis were the data related to drug 
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prescriptions (6,993 cases, 747 patients).  
In this study, all episodes of statin prescriptions claimed during July 2008 to June 2010(24 months) were extracted 
from the dataset since the patent of atorvastatin expired in July 2008 (6993 episodes, 747 persons). Statins included 
simvastatin (C10AA01), lovastatin (C10AA02), pravastatin (C10AA03), fluvastatin (C10AA04), atorvastatin (C10AA05), 
rosuvastatin (C10AA07) and pitavastatin (C10AA08). PaWLHQW¶V,'was de-identified, and under each drug prescription 
episodes, relevant data were derived. This included drug costs, quantity prescribed, visit dates, and prescribed days. 
Quantities prescribed were measured in daily defined doses (DDDs) [26].   
Patients were subsequently stratified by presence of statin claims (previously treated group) or absence of a statin 
claim (newly treated group) in the pre-index period to analyze the cohorts separately. It was hypothesized that there 
could potentially be differences in behavior between these two groups, based on the previous use of statins and 
previous publications [22, 24]. Patients where the interval from the last claim in the pre-index period to the first claim in 
the index period was more than 200 days (average interval = 525.25±230.97 days), were considered as newly treated.  
 
Statistical analysis  
Firstly, the descriptive time trend of prescriptions was conducted in order to identify prescribing trends after generic 
atorvastatin became available. In addition, the prescription quantity and time intervals between visits for prescriptions 
were compared according to the type of prescribed medicine, i.e. generic atorvastatin, originator atorvastatin and 
other statins. The coverage ratio, as calculated by dividing the quantity prescribed per each episode by time intervals, 
were also added for comparison. Means were tested for variance and compared by independent t-test, and 
proportions were compared using the Ɠ2-test. All comparisons were two-sided and performed at a 5% level of 
significance.  
Secondly, to identify factors contributing to generic atorvastatin prescriptions, we used a Mixed Logit Model with 
autocorrelation error in consideration of the repeated prescription episodes among the study sample. The dependent 
variable with a binary structure is coded as 1 for the generic atorvastatin prescription and 0 otherwise. To control the 
correlations among the repeated prescription episode for the same patient sampled randomly, the first-order 
autoregressive (AR(1)) was modeled in covariance structure [27-28]. 
The explanatory variables included demographic and socioeconomic characteristics (e.g. sex, age, education, 
insurance type), clinical characteristics, i.e. newly treated group or not and the number of comorbidities counting the 
number of 3-digit ICD for each episode, and provider characteristics, i.e. type of hospital, specialty. Medical institutions 
in Korea can be classified into five types: tertiary general hospitals (teaching hospitals, designated by the Minister of 
Health and Welfare), general hospitals (more than 100 beds), hospitals (more than 30 beds), clinics, and others that 
include heath centers and health care posts, 
All statistical tests were performed using SAS version 9.4. PROC GLIMMIX was applied to fit our bivariate model [29]. 
Ethical approval was not needed since all patient data was anonymised. This is similar to other studies of this    
nature undertaken with anonymized health insurance company data, such as those conducted in Europe and t
he US [6,12,13,17].  
 
Results 
Population characteristics 
Table 1 presents the basic characteristics of the 747 patients that were prescribed statins at least once during the 24 
months (July 2008±June 2010) after generic atorvastatin became available. Male patients accounted for 35.2%, mean 
age was 61.62 years, and 93.1% were NHI subscribers. Among the health care institutions, clinics occupied the 
highest proportion (56.7%). The average number of outpatient visits of the subjects during the observation period of 
24 months was 9.34.  
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Table 1. Basic characteristics of the study population (n=747) 
 Total Sample Previously treated Newly treated P-value 
 (N=747) (N=283) (N=464) 
Sex (male, %) 35.2 34.6 35.5 NS 
Age, mean(SD) 61.62(11.06) 62.96(9.76) 60.84(11.72) 0.0078 
Age group, N(%)     
 Less than 50 99(13.2) 26(9.2) 73(15.7)  
 50~59 209(28.0) 82(29.0) 127(27.4)  
 60~69 244(32.7) 112(39.6) 132(28.5)  
 70+ 135(26.1) 63(22.3) 132(28.5)  
Insurance status, N(%)    NS 
 NHI 698(93.1) 259(91.5) 439(94.6)  
 Medical Aid 49( 6.6) 24( 8.5) 25( 5.4)  
Education, N(%)    NS 
 <=Primary school 112(15.4) 36(13.0) 76(16.8)  
 Middle school 261(35.8) 105(38.0) 156(34.5)  
 High school 133(18.2) 52(18.8) 81(17.9)  
 College + 223(30.6) 83(30.1) 140(30.9)  
Visits by type of institutions, N(%)*  
 Tertiary general hospital 126(16.8) 24(16.1) 42(13.5) 0.0375 
 General hospital 180(24.1) 47(31.5) 61(13.2) NS 
 Hospital 76(10.2) 9( 6.0) 46(14.7) 0.0073 
 Clinics 424(56.7) 163(57.6) 261(56.1) NS 
 Others 54( 7.2) 12( 4.2) 42( 9.0) 0.0141 
Major comorbidities, N(%)     
 Hypertension 534(71.5) 245(86.6) 289(62.3) <0.0001 
 Diabetes 345(46.2) 167(59.0) 178(38.4) <0.0001 
 Stroke 135(18.1) 59(20.9) 76(16.4) NS 
 Depression 68(9.1) 30(10.6) 38(8.2) NS 
 Osteoporosis 120(17.5) 61(21.6) 59(12.7) 0.0014 
No. of visits per users during observational period   
 9.34(8.37) 13.95(9.36) 6.55( 6.23) <0.0001 
* Percent may over 100% 
 
When comparing the basic characteristics of the previously treated and newly treated groups, significant differences 
were observed in the mean age, type of the health care institutions, comorbidities, and the frequency of visits for 
treatment. The newly treated group had a slightly lower mean age than the previously treated group (p=0.0078), used 
tertiary general  hospitals less frequently (p=0.0375) while using hospitals (p=0.0073) more frequently, and showed 
lower rates of comorbidities such as hypertension, diabetes, and osteoporosis. Newly treated users visited health care 
institutes significantly less frequently than previously treated users did (6.55 vs. 13.95 times) (p<0.0001). Collating this, 
compared with previously treated users, newly treated users were generally younger, had fewer comorbidities and use 
health services less frequently.  
 
Patterns of Statins prescriptions 
Overall trend in statin utilization 
As shown in Table 2, overall monthly aggregate drug spending and utilization showed an increasing trend overtime. 
Spending on statins and volume prescribed have increased by 36.2% and 52.7% respectively between July 2008 and 
June 2010.  
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Table 2. Monthly aggregate spending and volume prescribed on statins 
 
Monthly spending Quantities 
KRW ǻ DDDs Ȟ 
July 2008 7,133,610 - 5,798 - 
Jun. 2009 8,768,838 22.9%  7,626 31.5% 
Jun. 2010 9,714,075 36.2%  8,857 52.7% 
ǻ*URZWKUDWHEDVHGRQ-XO\ 
KRW: Korean Won [1 USD=1,018.71 KRW as of July 2008] 
 
Figure 1 presents the prescription pattern of generic atorvastatin during the observation period. Monthly drug spending 
on generic atorvastatin sharply increased compared to its originator (see Fig.1 a). Monthly costs for generic 
atorvastatin were lower than the originator (Fig 1b) driven by lower quantities prescribed (Fig 1d) since the average 
price for generic atorvastatin was similar to that of originator atorvastatin (Fig.1 f). With respect to utilization, there was 
an appreciable growth in the prescribing of generic atorvastatin versus originator atorvastatin and other statins (lower, 
similar or marginal increase over time) (Fig 1c). This was driven by increasing number of patients receiving generic 
atorvastatin (Fig 1e) with similar monthly quantities prescribed per patient (Fig 1d). However, the prescribed dose for 
generic atorvastatin was lower than the originator (Fig 1d).  
 
Figure 1. Overall trend in drug utilization and number of patients prescribed after statins after atorvastatin lost its 
patent 
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1e) Number of patients prescribed statins per month 
 
1f) Unit price of each medication 
 
 
Note : Others include simvastatin, lovastatin, pravastatin, fluvastatin, rosuvastatin and pitavastatin 
 
Increase in number of patients prescribed statins per month 
As shown in Fig.1(e), there was a substantial increase in number of patients prescribed generic atorvastatin (240.5% 
increase from July 2008 to June 2010) as opposed to the originator (30.0%) and other statins (-10.9%). When the 
patients prescribed generic atorvastatin are divided into previously treated group and newly treated group, those 
prescribed generic atorvastatin increasingly belong to the newly treated group (Fig 2(a)).  
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Figure 2. Number of patients prescribed statins over time 
 
 
 
 
2c) No. of patient in the previously treated group 
 
Note : Others include simvastatin, lovastatin, pravastatin, fluvastatin, rosuvastatin and pitavastatin 
 
In other words, the entry of generics after the patent expiration of atorvastatin led to a rapid increase in the number of 
newly treated patients, with an appreciable number prescribed generic atorvastatin (50.9% in June 2010). Breaking 
down the number of the newly treated group by prescribed drug, there was increasing utilization of all statins; however, 
the number of the patients prescribed generic atorvastatin increased more rapidly than the other statins (Fig. 2(b)). 
This is a clear indication of the market expansion effect of generics in South Korea. Fig.2(c) shows the substitution 
effect of generic atorvastatin in the previously treated group DWWKHH[SHQVHRIERWKRULJLQDWRUDWRUYDVWDWLQDQGµRWKHU
VWDWLQV¶ZLWKDJUHDWHUHIIHFWRQµRWKHUVWDWLQV¶. While the number of patients prescribed generic atorvastatin tended to 
increase over time, the number of patients prescribed originator atorvastatin and other statins GHFUHDVHG µRWKHU
VWDWLQV¶ to a greater extent. This implies both originator atorvastatin and other statins are being substituted by generic 
atorvastatin to some extent in the previously treated group. 
Prescribing pattern of generic atorvastatin 
In Fig.1(d), it was verified that the prescription quantity of generic atorvastatin is lower than that of the originator 
atorvastatin or other statins. Table 3 presents the results of the detailed analysis of the prescription patterns of generic 
atorvastatin in comparison with those of the originator atorvastatin or other statins. 
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Table 3. Mean comparison of prescriptions episodes (N=6,339) 
 
Quantities prescribed 
(DDDs) 
Intervals Coverage ratio 
Prescribed medications     
Generic Atorvastatin  20.04 ± 15.21***  38.77 ± 38.11***  0.64 ± 1.82** 
 Originator Atorvastatin 29.80 ± 27.48 48.65 ± 40.00* 0.91 ± 3.47 
Other statins 30.59 ± 27.32 44.88 ± 44.19 0.79 ± 1.15 
Previously treated     
Generic Atorvastatin   21.20 ± 15.65***  37.93 ± 31.99*** 0.72 ± 2.57 
Originator Atorvastatin  32.84 ± 31.71  53.19 ± 39.80*** 0.92 ± 4.13 
Other statins  27.17 ± 23.54 45.45 ± 50.05 0.74 ± 0.61 
Newly treated     
Generic Atorvastatin   19.22 ± 14.83***  39.41 ± 42.21*  0.58 ± 0.89*** 
Originator Atorvastatin  25.67 ± 19.66 41.76 ± 39.35 0.89 ± 2.13 
 Other statins  27.17 ± 23.54 43.72 ± 51.37 0.91 ± 1.85 
Note: Data on other statins were used as the reference data in the statistical analysis.  
*p<0.5, **p<0.001, ***p<0.0001 
First, the mean prescribed quantity in DDDs of generic atorvastatin is 20.04, which is significantly lower when 
compared with other groups (p=<0.0001), whereas originator atorvastatin and other statins did not show any 
significant differences.  
The intergroup comparison of average prescription quantities yielded the following findings. Firstly, the previously 
treated group was prescribed generic atorvastatin at a significantly lower quantity compared to the prescription 
quantities of other originator atorvastatin and the other statins (p<0.0001) (Table 3), whereas no differences in 
prescription quantities were observed between the originator atorvastatin and the other statins. The same pattern was 
exhibited in the newly treated group. Overall then, the prescription quantity of generic atorvastatin was significantly 
lower than other statins including originator atorvastatin.  
However, since the prescription quantity depends on the interval between prescription refills, it is essential to consider 
prescription interval additionally. The mean interval for seeing a physician for prescription renewal was significantly 
lower in the case of generic atorvastatin (38.77days; p<0.0001), whereas original atorvastatin and other statins did not 
show any significant differences. Comparison of the previously treated and newly treated groups yielded results 
slightly different from the quantities prescribed. To find out the reason for this discrepancy, we calculated the coverage 
ratio by dividing the prescribed quantity at time of visiting a physician for prescription renewal by the interval, the span 
of time for its consumption. The coverage ratio represents the medication adherence for the prescribed quantities in 
the span of time till the next visit to physician for prescription renewal. A coverage ratio lower than 1 suggests that the 
patient missed at least 1 dose of medication. According to the coverage ratio in Table 3, there was underutilization of 
generic atorvastatin prescriptions among newly treated patients. The coverage ratio for those episodes is 0.58 which 
was significantly lower than the others (p<0.0001).  
 
Factors contributing to generic atorvastatin prescriptions 
Table 4 presents the results of the mixed logistic model based on the AR(1) covariance matrix for the factors 
contributing to the prescription of generic atorvastatin after the patent expiration of its branded version.  
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Table 4. Mixed logit model results on factors contributing to generic atorvastatin prescription 
*p<0.1, **p<0.05, ***p<0.0001 
AR(1): first order auto-regressive process. 
 
As mentioned, we considered the mixed logit model adjusting demographic and socioeconomic factors, clinical factors 
DQGSURYLGHU¶VFKDUDFWHULVWLFV. Demographic and socioeconomic status were not significantly associated with  generic 
atorvastatin prescriptions. Only the age group of 60~69 were more likely to be prescribed generic atorvastatin 
[OR=1.42; CI: 1.01-2.00]. The greater number of comorbidities, the less likely patients will be prescribed generic 
atorvastatin [OR=0.96; CI: 0.94-0.98]. Newly treated patients were 2.59 times more likely to receive prescriptions for 
generic atorvastatin than previously treated patients [CI: 2.07-3.23] (Table 3). 
When comparing generic atorvastatin prescriptions among healthcare providers by type and their specialty, then 
taking a tertiary general hospital as reference, the odds ratio was 3.97 [CI: 2.60±6.06] for a general hospital, 9.23[CI: 
5.86±14.56] for a secondary hospital, and 9.81 [CI: 6.58±14.61] for a clinic. From this finding, it can be inferred that 
secondary hospitals and clinics prescribe generic atorvastatin more frequently than tertiary hospitals, which reached 
statistical significance. Physician specialties made little difference. In summary, the availability of generic atorvastatin 
resulted in an increase in the number of prescriptions for statins, mostly through the newly treated group, and clinics 
and secondary hospitals are key drivers of generic atorvastatin prescriptions.  
 
Discussion 
In this study, we firstly identified market expansion induced by newly entered generic atorvastatin in South Korea. 
Specifically, a substantial proportion of generic atorvastatin prescriptions were dispensed to the newly treated group 
and the increase in the number of newly treated patients was primarily responsible for the increase in the utilization of 
generic atorvastatin while the market entry of generic atorvastatin has a partial substitution effect in the previously 
treated group. Thus, the market expansion effect of the market entry of generic atorvastatin can be explained by the 
increase in the number of newly treated patients receiving prescriptions for generic atorvastatin. 
Furthermore, we investigated the factors surrounding the prescribing of generic atorvastatin once it entered the market 
place as well as the prescribing patterns of the other statins including originator atorvastatin. The findings showed that 
the number of patients prescribed generic atorvastatin rapidly increased and that the newly treated group of patients 
Parameter SE
Intercept 3.059-      ***    0.356 0.05    [0.03: 0.07]
Sex (ref=female) Male 0.080-         0.131     0.92 [0.71: 1.19]
Age (ref = < 50)  50~59 0.189-         0.164     0.83 [0.60: 1.15]
 60~69       0.351 *    0.172     1.42 [1.01: 2.00]
 70+       0.279    0.184     1.32 [0.92: 1.91]
Education (ref: <=primary ) Middle school       0.165    0.168     1.18 [0.85: 1.64]
High school 0.002         0.201     1.00 [0.68: 1.49]
College +       0.233    0.199     1.26 [0.86: 1.87]
Insurance type (ref=medical aid) NHI -     0.027    0.189     0.97 [0.53: 1.77]
Number of comorbidities 0.044-      ***    0.010     0.96 [0.94: 0.98]
Newly treated group (ref=previously treated)       0.951 ***    0.003     2.59 [2.07: 3.23]
Type of Hospital General hospitals       1.378 ***    0.213     3.97 [2.60: 6.06]
(ref=teaching hospitals) Hospitals       2.223 ***    0.229     9.23 [5.86: 14.56]
Clinics       2.283 ***    0.201     9.81 [6.58: 14.61]
Specialty (ref=others) Internalist 0.057-         0.076     0.95 [0.81: 1.10]
AR(1) 0.729 *** 0.008
Residual 1.021 *** 0.029
-2 log Likelihood
Estimates Odds Ratio [95% CI]
25525.50
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was mostly responsible for this increase. We also showed that the average prescribed dose of generic atorvastatin 
was significantly lower in the newly treated group compared to originator atorvastatin or other statins and that clinics 
and secondary hospitals were key players implicated in boosting the prescription of the generic versions. Further 
research will focus on the rationale for this since such prescribing habits need to be addressed to ensure the full 
health gain from prescribing statins is accrued in these patients.  
As mentioned, in many countries there is an increasing trend is to promote the utilization of lower-priced generics 
versus originators and patented products in a class where all products are seen as therapeutically equivalents. such 
as the statins, to contain healthcare costs in the face of continuing resource pressures [6, 12-14, 16-17, 30-32]. In this 
study, we could verify two effects generated by the entry of generic medicines in Korea: substitution effect and market 
expansion effect. While the substitution effect was demonstrated in the previously treated group, the market expansion 
effect was observed in the increase in the utilization of statins in the newly treated group especially generic 
atorvastatin (Figs 2a and 2b).  
In Korea, given that there is no marked price difference between originals and generics and no specific demand-side 
measures encouraging the use of generics, changes in the overall market structure caused by the entry of new 
generic drugs are of particular interest. Furthermore, in the face of the situation in which the entry of generic 
medicines appears to act as a driving force for increasing rather than for reducing drug spending, policies regarding 
generic drugs will have to be reconsidered in Korea alongside the appropriateness of prescribing. 
One of the limitations of this study is that we did not explore the rationale behind the considerable increase in the 
number of newly treated persons (Fig 2b). This is partly attributable to the nature of the NHI claims data lacking 
laboratory data or diagnosis information, unlike in other countries, which makes it difficult to identify accurate 
diagnosis including ICD-10 data. For the same reason, the characteristics of new patients could not be determined 
more clearly by adjusting the rapidly increased number of new patients with respect to any increases in  cases of 
hyperlipidemia. This will have to be addressed in a future study once epidemiological data on hyperlipidemia are 
secured alongside research among physicians to ascertain their rational for any rapidly increasing prescribing of 
statins following the availability of generic atorvastatin.  
This can include increased awareness of the need to treat patients well with established CV disease to reduce 
subsequent morbidity and mortality, as seen in the UK with their multiple initiatives [12].  
One potential rationale behind the rapid increase in the number of patients prescribed statins in the newly treated 
group may be partly explained by the physician-induced demand in Korea as seen in a study conducted by Kim (2002), 
i.e. increase in the number of patients initially diagnosed in clinics following greater promotion and marketing activities 
among pharmaceutical companies, thus contributing to the overall increase in the healtKFDUHFRVWVDQGSDWLHQWV¶YLVLWV
[33]. In other words, physician-induced demand can be considered partly responsible for the appreciable increase in 
number of new patients prescribed statins (Fig 2b).  
In addition, previous studies on physicians¶ prescribing behaviors identified financial incentives associated with 
increased prescribing. It has been seen in a number of studies that the size of mark-up and rebates [34-38] as well as 
gifts offered by pharmaceutical manufacturers [39-45] greatly influenced prescription patterns. Korean domestic 
pharmaceutical companies are more focused on generics than newly developed medicines [46], and the patent 
expiration of a high volume medicine such as atorvastatin can give rise to a simultaneous release of over 100 branded 
generic medicines [47]. However, this strong competition among generic manufacturers is not associated with lower 
prices as seen in a number of other countries where prices of generic statins can be as low as 2% to 4% of pre-patent 
loss prices with market competition [12,17,48]. As a result, leading to generic manufacturers pursuing illegal 
promotional activities, such as providing physicians kickbacks for prescribing their particular products in view of the 
margins involved. Physicians received kickbacks of up to 20% of the value of the prescription [49]. Under these 
circumstances, it may be inferred that the maximization of financial incentives through higher prescription performance 
is sought by creating new patients for prescription episodes whilst encouraging the prescribing low dose generic 
statins to minimize side effects, although evidence for this hypothesis has yet to be established. Ways to address this 
include greater education of physicians regarding optimal doses of statins prescribed as well as encouraging 
International non-proprietary name (INN) prescribing as opposed to the prescribing of branded generics as seen in 
some European countries [12]. This would reduce the incentive of different generic manufacturers to appreciably 
increase the market after patent expiry through their promotional activities. In addition, appreciable price decreases 
could be achieved if pharmacists were only reimbursed the price of lower priced generics with manufacturers striving 
to achieve this as seen for instance in the United Kingdom [12]. INN prescribing also reduces patient confusion if they 
are dispensed different branded generics without a full explanation, potentially leading to either under- or over-dosing 
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[50].    
Conclusion 
In conclusion, we believe this study appreciably adds to the literature in that it identified current prescription patterns 
characterized by a substantial increase in the prescribing of generics in new patients in Korea following their entry, the 
minor substitution effect on previously prescribed patients as well as the major market expansion effect generated by 
the rapid increase in the number of new patients prescribed generics. In follow-up studies, other issues related to the 
entry of generic drugs will be addressed, such as physician-induced demand, the quality of prescribing and rational 
use of drugs.  
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